By: Danielle Casaus
Dr. Shah completed his PGY1 pharmacy residency program at Wellstar Atlanta Medical Center (2022) followed by a PGY2 specialty pharmacy residency in infectious disease at the University of Florida Health Shands Hospital (2023). Dr. Shah currently serves as an Infectious Diseases Clinical Pharmacy Specialist at Penn Medicine Lancaster General Hospital. His research interests include antimicrobial stewardship, gram-negative resistance, and diagnostic stewardship.
Dr. Shah's most recent project is completing his PGY2 research manuscript that evaluated the gray area of rifampin (RIF) therapy in prosthetic joint infections. This project explored the benefit of adjunctive rifampin (RIF) to standard of care (non-RIF) therapy for prosthetic joint infections caused by staphylococcal species. The data is mixed on whether adjunctive rifampin provides a benefit for patients who received a Debridement, Antibiotics, and Implant Retention (DAIR) or 1-stage exchange surgical treatment for prosthetic joint infections. His research showed that patients who received RIF had a statistically significant lower rate of treatment failure, highlighting the benefit of rifampin in treating prosthetic joint infections caused by staphylococcal species following a DAIR.
Comments